Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
Pablo García‐Pavía(Universidad Francisco de Vitoria), Aleš Linhart(Charles University), Claudio Rapezzi(University of Ferrara), Urs Eriksson(GZO Spital Wetzikon), Ingrid Kindermann(Baker Heart and Diabetes Institute), Michael Arad(Tel Aviv University), Sabine Pankuweit(Universitätsklinikum Gießen und Marburg), Marianna Fontana(Amyloidosis Foundation), Massimo Imazio(University of Udine), Alida L.P. Caforio(University of Padua), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew J. Maurer(Mayo Clinic in Arizona), Stéphane Heymans(Maastricht University Medical Centre), Yehuda Adler, Arnt V. Kristen(Heidelberg University), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Mayo Clinic in Arizona), Esther González-López(Centro de Investigación en Red en Enfermedades Cardiovasculares), Giampaolo Merlini(University of Pavia), Ivana Burazor(University of Belgrade), Angelos G. Rigopoulos(Luther University), Antonis Pantazis(Harefield Hospital), Antonio Brucato(Azienda Ospedaliera Fatebenefratelli e Oftalmico)
Cited by 1,142
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
|European Heart Journal|2015|2.6k